EFFICACY OF TOPICAL MINOXIDIL 5% AND BETAMETHASONE VALERATE 0.1% VERSUS BETAMETHASONE VALERATE 0.1% MONOTHERAPY IN NON-SEGMENTAL VITILIGO


Roshna Ahmed Ali a and Ali Mozan Dhahir El-Ethawi b



College of Medicine, University of Sulaimani, Kurdistan Region, Iraq.
b Department of Cardiology, Sulaymaniyah Teaching Hospital, Interventional Cardiology Center, Kurdistan Region, Iraq.


Submitted: 17/4/2022; Accepted: 1/8/2022; Published: 21/9/2022



ABSTRACT 


Background 

Vitiligo is a common depigmentation disorder of the skin. Circumscribed amelanotic patches characterize it due to the destruction of melanocytes. It affects 0.5-2.0% of general population. Many combinations of medical therapies have been studied, but the optimal treatment has yet to be identified.


Objectives 

To evaluate the efficacy of topical minoxidil 5% plus betamethasone valerate 0.1% compared to betamethasone valerate 0.1% monotherapy in the treatment of non-segmental vitiligo


Materials and Methods

This open-label, comparative, therapeutic clinical trial was conducted at the Sulaimani dermatology teaching center from May 2021 to February 2022. In this trial, 30 patients with non-segmental vitiligo were divided into two groups, 15 patients each; group A treated with topical minoxidil 5% spray & betamethasone valerate 0.1% cream, and group B was treated with betamethasone valerate 0.1% cream alone, the two regimens were used twice a day and patients were followed up for three months.


Results

The mean percentage of depigmentation in groups A and B were (21.9%) & (16%), respectively. 


Conclusion

Topical minoxidil & betamethasone valerate combination achieved a higher grade of depigmentation, especially in the vitiligo of the hair-bearing areas of the head & neck. However, there was no significant difference compared to betamethasone valerate alone (P value = 0.8).



KEYWORDS

Topical minoxidil, Non-segmental vitiligo.